35 results about "Hypercoagulable states" patented technology

The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.

The invention discloses a composite kidney-benefiting medicine and belongs to Chinese herbal composite medicine. The composite kidney-benefiting medicine comprises astragalus, angelica sinensis, red peony root, rhizoma chuanxiong, glossy privet fruit, eclipta, lalang grass rhizome, moutan bark, fructus kochiae and glycyrrhiza. The composite kidney-benefiting medicine can effectively cure pure simple hematuresis and hematuresis proteinuria, comprises immune globulin A (IgA) nephropathy, anaphylatic purpura nephritis, nephrotic syndrome, comprises nephritis type with hematuresis, can confront side effect of nephrotic syndrome which is cured by hormone, can play roles in promoting blood circulation to remove blood stasis and preventing and curing hypercoagulable state and has the advantages of being prominent in curative effect, convenient to take and good in taste.

The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject.

The invention relates to the technical field of medicine, in particular to a new application of scutellarin, and provides the application of the scutellarin in preparing medicine for reducing pathological changes of kidney tissue and the application of the scutellarin in preparing medicine for treating nephritis. The new application of the scutellarin is proved by experiments to show that the intragastric administration is continuously performed on nephritis model rats with the scutellarin in the dose of 20 mg / kg and 40 mg / kg for eight weeks, the proteinuria of the model animals can be obviously reduced, hypoproteinemia, hyperlipidemia and the hypercoagulable state of blood can be corrected, the serum lipid peroxidation product content of the model rats can be lowered, the expression of TNF-alpha in the kidney tissue can be inhibited, and a protection effect on the kidney tissue and a good improvement effect on the kidney function are achieved; in addition, the maximum dose of intragastric administration on the rats is equal to and more than 18 g / kg, and obvious acute toxicity reaction and death do not occur on the animals.

The invention provides a traditional Chinese medicine composition for treating primary nephrotic syndrome. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients: membranous milkvetch root, liquorice root, epimedium herb, medicinal Indianmulberry root, flastem milkvetch seed, sappan wood, cowherb seed, zedoary tumeric, common anemarrhena rhizome, amur corktree bark, barbed skullcap herb, radix salviae miltiorrhizae, rice bean, common yam rhizome, manyprickle acanto-panax root, gordon euryale seed, rhizome, sharpleaf galangal fruit, fourstamen stephania root, walnut kernel, glabrous greenbrier rhizome, sinkiang arnebia root, sevenlobed yam rhizome, cochinchnese asparagus root, belvedere fruit, medcinal evodia fruit, lychee seed, dendrobium, glossy privet fruit and Chinese angelica. The traditional Chinese medicine composition provided by the invention is used for treating the primary nephrotic syndrome, can antagonize the side effects of hormones and other Western medicines, improve the blood flow of kidney, reduce urine proteins, retard kidney damages, improve the hypercoagulable state of a patient, consolidate efficacy, reduce the rebound phenomenon of the disease and realize few side effects, low recurrence rate and high complete relief rate, and has a certain efficacy for treating the primary nephrotic syndrome.

The invention discloses a Chinese medicinal composition for preventing and treating diabetes and a preparation method thereof. The Chinese medicinal composition consists of the following components in parts by weight: 10-20 parts of vervain, 1-2 parts of typhonium giganteum, 10-20 parts of barley root, 10-20 parts of coptis root, 10-20 parts of black fungus, 10-20 parts of white fungus, 10-20 parts of sticky rice, 10-20 parts of barley rice, 10-20 parts of buckwheat, 5-50 parts of honey and 50-100 parts of vinegar. Natural animal and plant medicinal materials are taken as raw material sources, and diabetics syndrome and nephrotic syndrome are treated by using the comprehensive function of various Chinese medicinal components. As proved by acute toxicity test and long-term toxicity test, the Chinese medicinal composition is nontoxic to human body and good in medicinal effect and has the effects of improving the hypercoagulable state, improving blood fat, reducing blood sugar, dissolving thrombi, dredging microcirculation and improving the immunity of organisms.

The invention discloses a method for detecting hemostatic capability. The method comprises: preparing anticoagulant blood from venous blood and anticoagulant with 0.13mol / L of sodium citrate in a volume ratio of 9:1; centrifuging an anticoagulant blood sample for 15 minutes at a speed of 3,000 r / min and sucking plasma to be detected; performing OHP determination of overall hemostatic capability, OCP determination of overall blood coagulation capability and OFP judgment of overall fibrinolytic capability; indicating the existence of blood coagulation disturbance when OCP and OHP are less than the lower limit of normal reference values; indicating the existence of hypercoagulable state when the OCP and the OHP are greater than the upper limit of the normal reference values; and indicating the reduction of fibrinolytic function when OFP value is less than 41.61 percent. The method has the advantages of good stability and repeatability, easy operation and low cost, and is worthy of popularization.

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and / or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.

The invention discloses a traditional Chinese medicine composition for treating diabetes and a preparation method thereof. The composition is composed of 19 traditional Chinese medicines including: fresh porcine pancreas, white muscardine silkworm, hirudo, endothelium corneum gigeriae galli, American ginseng, panax notoginseng, balsam pear, schisandra chinensis, lance asiabell roots, fructus amomi, walnut kernels, fructus lycii, rhizoma atractylodis, black soybean, hawthorn, astragalus membranaceus, wild black fungus, kudzu vine root and Chinese yam. According to the invention, a very critical and essential object in traditional Chinese medicine is really achieved. Not is blood glucose simply reduced but a damaged pancreas is repaired. A sufficient amount of insulin can be secreted; excessive sugar in blood can be neutralized; hypercoagulable state can be improved; microcirculation is unblocked; and complications in a diabetic patient is reduced or alleviated.

The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to an anti-venous thrombosis traditional Chinese medicine prescription, a preparation and a preparation method. The traditional Chinese medicine prescription is mainly prepared from the following raw materials: herba lycopi, cacumen biotae, cortex phellodendri, radix et rhizoma rhei, folium artemisiae argyi, rhizoma coptidis, caulis impatientis, fructus xanthii and herba taraxaci. The invention also provides the preparation containing the traditional Chinese medicine prescription, namely oneof lotions, liniments, ointments, pigmentums, tinctures, pastes, aerosols, sprays, powder, plastics, gels and patches. The experiment results show that the traditional Chinese medicine prescription and the preparation, provided by the invention, can prevent venous thrombosis, can prolong the clotting time and can be used for preventing and treating venous thrombosis caused by post-operation immobilization, long-term bed, hypercoagulable state of blood, and the like, and eczema on the skin surface of a long-term bedridden patient.

The invention relates to a medicine for treating hypertension, and in particular relates to a traditional Chinese medicinal composition capable of lowering blood pressure. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicinal materials by weight: 15-40 g of radix polygoni multiflori, 12-30 g of radix notoginseng powder, 10-30 g of pearl powder, 5-20 g of rhizoma ligustici wallichii, 10-30 g of stir-baked cortex eucommiae, 15-40 g of pulp of dogwood fruits, 5-25 g of rhizoma alismatis, 20-60 g of ramulus uncariae cum uncis, 10-60 g of spica prunellae, 10-90 g of longan pulp, 10-20 g of lily bulb, and 6-10 g of rhizoma anemarrhenae. According to the traditional Chinese medicinal composition, the traditional Chinese medicinal materials which are non-toxic and harmless and are free of side effects to the human body are adopted as the raw materials, the traditional Chinese medicinal composition can be directly taken without the decoction operation, the effective ingredients capable of lowering blood pressure in the traditional Chinese medicinal materials can be well absorbed, the treatment curative effects are good, meanwhile, the hypercoagulable state of blood can be improved, the microcirculation can be dredged, the immunity of the human body can be enhanced, the occurrence of hypertension complications can be alleviated, and both taking and carrying are extremely convenient.

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating non-small-cell lung cancer hypercoagulability. The traditional Chinese medicine is composed of, by weight, 8-16 parts of milkvetch roots, 8-16 parts of roots of woodland beakchervil, 8-16 parts of rhizoma atractylodis macrocephalae, 8-16 parts of salviae miltiorrhizae, 8-16 parts of saffron, 8-16 parts of hirudo, 6-14 parts of fructus aurantii, 6-14 parts of pericarpium citri reticulatae, 6-14 parts of pinellia ternate, 6-14 parts of twigs and leaves of Tibet lyonia, 8-16 parts of angelica sinensis, 8-16 parts of macrocarpa nucuma and 4-8 parts of radix glycyrrhizae. The traditional Chinese medicine composition for treating the non-small-cell lung cancer hypercoagulability can improve the hypercoagulable state of patients with advanced NSCLC and relieve symptoms of traditional Chinese medicine obviously. Obvious changes of blood routine, liver and kidney functions and electrocardiograms do not exist, and the safety of medication is good.

The invention provides a one-step homogeneous phase D-dimer detection kit and application thereof to detecting the D-dimer content. The kit comprises a D-dimer antibody coupling resisting light-emitting microballoon test solution (1), a D-dimer antibody coupling resisting light-sensitive microballoon test solution (2) and reaction holes capable of receiving and emitting light. Compared with the prior art, the kit has the advantages of being convenient to operate, fast in detection, high in sensitivity, good in accuracy and the like and is high in specificity. The kit is applied to monitoring the hypercoagulable state and thrombotic diseases, and the accuracy of monitoring the hypercoagulable state and the thrombotic diseases can be improved.

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

The invention discloses an animal model in a tranexamic acid induced hyper-coagulation state and a building method thereof. The building method is characterized in that a rat is gavaged for two times with tranexamic acid, and then the animal model in the tranexamic acid induced hyper-coagulation state can be formed during 2-12 hours; the operation is simple; the success rate of the model is high; and the hyper-coagulation state lasts a long time. The building method is simple to operate, and high in success rate of the model, and the hyper-coagulation state lasts a long time. With the adoption of the building method, the tranexamic acid based rat animal model in the hyper-coagulation state is successfully built; a foundation is provided to the study on related rat hyper-coagulation state; and a novel rate hyper-coagulation state animal model method is provided.

The invention discloses a traditional Chinese medicine composition with an anti-cancer effect and new application thereof. The traditional Chinese medicine composition for treating cancers is prepared from the following crude drugs: motherwort herb, flos carthami, Chinese prickly ash, leeches, Chinese angelica, ginsengs, white peony roots and the like. Effective components of the crude drugs sufficiently express the pharmacodynamics effect through methods including decoction, steam distillation, alcohol precipitation and the like. The preparation disclosed by the invention has a very good adjuvant therapy effect on malignant tumors, and can be used for remarkably reducing a blood hypercoagulable state, reducing microthrombosis and lowering secondary fibrinolysis.

The invention relates to a pharmaceutical composition with a thrombus prevention effect. The composition is prepared from the following traditional Chinese medicines in parts by weight: 42-78 parts ofmirabilite, 42-78 parts of rheum officinale, 42-78 parts of cacumen biotae, 21-39 parts of cortex phellodendri, 21-39 parts of mint, 21-39 parts of herba lycopi, 4.5-6.5 parts of borneol and 10.5-19.5 parts of cassia twigs. Through local external application, the composition can obviously reduce thrombus occurrence rate caused by PICC catheterization; the occurrence rate of related symptoms of the PICC catheterization, such as local swelling and pain and bleeding, is also obviously reduced; and thrombus related indexes, such as D dimer and FIB, are obviously reduced compared with those of a control group. The pharmaceutical composition disclosed by the invention has an obvious effect in the aspect of preventing thrombosis, can prevent and treat the hypercoagulable state of blood, conformsto the concept that the thrombus caused by the PICC catheterization depends on prevention, is safe, convenient and economical in prevention process, brings more benefits to patients, and improves thelife quality of tumor chemotherapy patients.

The invention relates to chenodeoxycholic acid and application thereof. Specifically, the invention provides application of a compound as shown in a formula (I) in preparation of drugs used for resisting platelet aggregation and thrombogenesis, for preventing diseases related to activation of blood platelet disorders and for treating diseases related to activation of blood platelet disorders, wherein the formula (I) is described in the specification. The chenodeoxycholic acid disclosed in the invention is capable of resisting aggregation and spreading of platelets and can be used as a novel anti-platelet aggregation and antithrombus drug in treatment of diseases related to activation of blood platelet disorders, wherein the diseases includes but are limited to thrombotic diseases, viral diseases with a hypercoagulable state, tumorous diseases, coronary heart disease, apoplexia, hypertension, leukemia, disseminated intravascular coagulation (DIC), etc.

The invention discloses application of Shenkang injection or Shenkang injection and an anticoagulant in preparing a drug for preventing and treating deep vein thrombosis caused by orthopaedics major operations. Proved by animal experiments, the Shenkang injection is capable of obviously reducing the whole blood viscosity, the plasma viscosity and the hematokrit of lower-limb deep vein rats and rabbits, obviously prolonging the thrombin time, the prothrombin time and partial thromboplastin time, increasing the content of SOD in blood and reducing the content of MDA, thereby improving the hypercoagulable state of the blood and reducing infiltration of the inflammatory medium; and in addition, the Shenkang injection is capable of obviously reducing the probability of the orthopaedics major operations causing the lower-limb deep vein thrombosis, and enhancing the postoperative immunity.

The medicine for the treatment of nephritis provided by the present invention includes the extract of the branch of the branch, and the extract of the branch of the branch is prepared according to the following method: firstly, the branch of the branch of the branch is soaked in petroleum ether, and the dregs are obtained after reflux extraction; After the slag is refluxed and extracted in ethanol, the extract of the seeds of the sage is obtained; the extract of the seeds of the sage is purified by using a macroporous adsorption resin to obtain the extract of the sage. Experiments show that the medicine provided by the invention has a therapeutic effect on rats with chronic nephritis; the medicine provided by the invention has a significant diuretic effect; during the occurrence and development of chronic nephritis, the blood coagulation mechanism disorder generally exists in the body and is in a hypercoagulable state. And it is an important factor for the continuous development of lesions and the progressive decline of renal function. The medicine provided by the invention can significantly reduce high shear, low shear and plasma specific viscosity, indicating that it has a significant effect on improving the hypercoagulation state.

The invention discloses an animal model of hypercoagulant state of rats induced by ethanamine and a construction method thereof. The present invention uses phensulfame to intervene, and after three intraperitoneal injections, a hypercoagulant state is formed within 1.5 to 9 hours, the operation is simple, the success rate of the model is high, and the hypercoagulant state lasts for a long time. The present invention successfully establishes an animal model of rat hypercoagulant state based on the phenetamine drug, which can lay a foundation for the research on rat hypercoagulant state, and is a new type of animal model method of rat hypercoagulant state.

The invention discloses an external traditional Chinese medicine for adjuvant therapy of cancer. The external traditional Chinese medicine is characterized by being mainly prepared from cordyceps sinensis, felwort, hedyotis diffusa, Chinese lobelia, liquorice, ochre, borneol, murdannia bracteata, lespedeza cuneata, lycopodium clavatum and pine needle, and a preparation method of the external traditional Chinese medicine comprises the steps of mixing and soaking. The traditional Chinese medicine composition is compatible with traditional Chinese medicine components capable of promoting blood circulation to remove blood stasis, so that blood circulation is increased, the hypercoagulable state of blood is changed, the medicine can enter cancer tissues more easily, the concentration of the medicine in a tumor body is improved, and in addition, the medicine further has the effects of resisting inflammation, resisting infection and easing pain; and middle and advanced tumor patients are often accompanied with inflammation and have symptoms such as fever, the symptoms are regarded as 'stasis toxin accumulation' or 'blood stasis accumulation' in traditional Chinese medicine, and a better effect can be achieved by combining heat-clearing and toxin-removing medicines and blood-activating and stasis-removing medicines in the formula. Meanwhile, cancer patients are often accompanied with pain symptoms, and the traditional Chinese medicine is further compatible with evil-expelling and healthy-energy-strengthening medicines, such as liquorice and borneol, so that the traditional Chinese medicine has a good pain relieving effect.

The invention relates to the field of medicine formulas, in particular to a compound kidney-tonifying medicine. The compound kidney-tonifying medicine is characterized by being prepared from the following raw materials in parts by weight: 25-35 parts of fructus broussonetiae, 20-30 parts of raspberry, 15-30 parts of lysimachia christinae hance, 10-20 parts of morinda officinalis, 25-35 parts of agastache rugosus, 10-15 parts of kusnezoff monkshood root, 15-25 parts of herba siegesbeckiae, 15-20 parts of salsola collina, 20-35 parts of pyrola, 15-25 parts of phyllanthus ruinaria, 15-20 parts of pyrrosia lingua, 20-30 parts of tribulusterrestris, 15-25 parts of radix dipsaci, 15-25 parts of corydalis cheilanthifolia, 15-25 parts of pericarpium arecae, 20-25 parts of polygonatum odoratum, 15-25 parts of centella asiatica and 20-25 parts of armstrong, wherein the raw materials are mixed and soaked with water, are decocted and deslagged to obtain filtrate. The compound kidney-tonifying medicine is capable of effectively treating asymptomatic hematuria and hematuria and proteinuria, helping hormone treat nephrotic syndrome, withstanding the side effects of the hormone, and playing roles in promoting blood circulation to remove blood stasis and preventing and treating a hypercoagulable state. The compound kidney-tonifying medicine has the advantages of significant and accurate curative effect, low cost and no obvious toxic or side effect.

The present invention discloses use of sea cucumber glycosaminoglycan in the preparation of drugs. In particular, the present invention relates to use of medical use of sea cucumber glycosaminoglycan, and more particularly to use of depolymerized sea cucumber glycosaminoglycan or natural molecular segments of sea cucumber glycosaminoglycan with a weight average molecular weight greater than 54,500 Da in the preparation of a drug for the prevention and treatment of thromboembolic diseases. Thromboembolic diseases include atherosclerotic thrombotic diseases, venous thromboembolic diseases, hypercoagulable states and postoperative thrombosis or treatment of postoperative thrombi. The present invention has a wide treatment window for thromboembolic diseases, has a higher level of safety, and has good development and research value.

The invention provides a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, belonging to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases is prepared from schizonepeta, divaricate saposhnikovia root, Japanese buttercup herb, golden cypress, coptis chinensis, dragon's blood, panax notoginseng, verdigris, safflower, java brucea fruit, sweet wormwood, cortex dictamni and oleum menthae. The traditional Chinese medicine composition disclosed by the invention has main effects of regulating vital energy, invigorating the circulation of blood, dissipating blood stasis and preventing infection so as to achieve the effects of unblocking blood vessels, promoting blood and qi circulation, removing blood stasis for promoting tissue regeneration, dredging the channel, regulating internal organs, improving brain circulation and improving hypercoagulable states of blood, such as thick, coagulated, viscosity and gathered; and therefore, the traditional Chinese medicine composition can be used for treating cardiovascular and cerebrovascular diseases.

The invention discloses an etamsylate induced rat hypercoagulable state animal model and an establishment method thereof. According to the model, etamsylate is adopted for interference, three times of intraperitoneal injection are implemented, then a hypercoagulable state is achieved within 1.5-9 hours, the operation is simple, the model success rate is high, and the hypercoagulable state can last for a relatively long time. The rat hypercoagulable state animal model based on an etamsylate medicine is successfully established, a base for related rat hypercoagulable state research is made, and the establishment method is a novel rat hypercoagulable state animal model method.

The invention relates to chenodeoxycholic acid and a use thereof. The invention concretely comprises uses of the compound shown in the formula (I) in preparation of drugs for resisting platelet aggregation and thrombogenesis and preventing and treating platelet abnormal activation-related diseases. The chenodeoxycholic acid has effects of resisting platelet aggregation and spreading, can be used as a novel platelet aggregation-resistant and antithrombotic drug for treating blood platelet abnormal activation-related diseases such as thrombotic diseases, hypercoagulable state viral diseases, tumors, coronary heart diseases, apoplexy, hypertension, abdominal aortic aneurysm, leukemia and disseminated intravascular coagulation (DIC).